BMO Capital Maintains Outperform on Corteva, Lowers Price Target to $95

Benzinga Newsdesk www.benzinga.com Negative 92.2%

Neg 92.2% Neu 0% Pos 0%

BMO Capital analyst Joel Jackson maintains Corteva (NYSE:CTVA) with a Outperform and lowers the price target from $100 to $95.